Dae Yul Yang

Dae Yul Yang

Auto-generated profile, based on publicly available information

Dae Yul Yang

Department of Urology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2003 in Journal of Andrology
Verified
Journal Article
Open access
PDF file
SLSomboon Leungwattanakij
Somboon Leungwattanakij
TBTrinity J. Bivalacqua
Trinity J. Bivalacqua
MUMustafa F. Usta
Mustafa F. Usta
DYDae‐Yul Yang
Dae‐Yul Yang
JHJae‐Seog Hyun
Jae‐Seog Hyun
WHWayne J.G. Hellstrom
Wayne J.G. Hellstrom
The etiologies of erectile dysfunction (ED) after nerve‐sparing radical prostatectomy have not been clearly elucidated. The aim of this study was to evaluate the effects of cavernous nerve injury on cavernous fibrosis, and to consider measures to prevent irreversible damage to the cavernous tissues. Twenty male Sprague‐Dawley rats constituted the study population. The animals were divided into 2 groups; group 1 consisted of sham‐operated rats (n = 10), and group 2 consisted of rats that underwent incision of both cavernous nerves (n = 10). Three months later, all rats underwent intracavernous papaverine injection (300 and 600 mg), and intracorporal pressures were recorded. Transforming growth factor‐β1 (TGF‐β1) messenger RNA (mRNA) expression from rat penile tissue was measured using reverse transcriptase‐polymerase chain reaction. Hypoxia‐inducible factor‐1α (HIF‐1α), TGF‐β1, and collagen I and III protein expressions were determined by Western blot analysis and immunohistochemical staining. Erectile function as studied with intracavernosal papaverine injection and histological analysis of penile cross‐sections at 3 months was similar in both groups. TGF‐β1 mRNA expression, HIF‐1α, TGF‐β1, and collagen I and III protein expressions were significantly greater in the neurotomy group. Immunohistochemical staining for TGF‐β1, HIF‐1α, and collagen III were qualitatively more positive in the neurotomy group, whereas collagen I staining was similar. This study demonstrates an increase in TGF‐β1, HIF‐1α, and collagen III synthesis in rat cavernosal smooth musculature after cavernous neurotomies. In theory, cavernous fibrosis may be reduced by employing various vasoactive agents or interventions that increase oxygenation to the corporal tissues during the postoperative period.

1 November 2008 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
JPJae-Seung Paick
Jae-Seung Paick
TATai Y. Ahn
Tai Y. Ahn
HCHyung K. Choi
Hyung K. Choi
WCWoo-Sik Chung
Woo-Sik Chung
JKJe J. Kim
Je J. Kim
HJHyung-Gi Jung
Hyung-Gi Jung

1 April 2008 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
JPJae-Seung Paick
Jae-Seung Paick
SKSae Woong Kim
Sae Woong Kim
DYDae Yeol Yang
Dae Yeol Yang
JKJa Jong Kim
Ja Jong Kim
SLSung Won Lee
Sung Won Lee
SKSae Chul Kim
Sae Chul Kim

1 August 2011 in European Urology
Verified
Journal Article
Closed access
CZChen Zhao
Chen Zhao
SKSae Woong Kim
Sae Woong Kim
DYDae Yul Yang
Dae Yul Yang
JKJe Jong Kim
Je Jong Kim
NPNam Cheol Park
Nam Cheol Park
JPJong Kwan Park
Jong Kwan Park

1 October 2003 in Journal of Urology
Verified
Journal Article
Closed access
MUMustafa F. Usta
Mustafa F. Usta
TBTrinity J. Bivalacqua
Trinity J. Bivalacqua
DYDae Yul Yang
Dae Yul Yang
ARAnshiya Ramanitharan
Anshiya Ramanitharan
DSDavid R. Sell
David R. Sell
WHWayne J.G. Hellstrom
Wayne J.G. Hellstrom
Purpose: Erectile dysfunction (ED) is frequently associated with diabetes mellitus. We determined if advanced glycation end products (AGEs) are involved in ED and investigated if the select...

1 August 2017 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
SKSae Woong Kim
Sae Woong Kim
NPNam Cheol Park
Nam Cheol Park
SLSeung Wook Lee
Seung Wook Lee
DYDae Yul Yang
Dae Yul Yang
JPJong Kwan Park
Jong Kwan Park
JHJae Seog Hyun
Jae Seog Hyun
Background: Phosphodiesterase type 5 inhibitors and α-adrenergic blocking agents (α-blockers) are widely used for the treatment of erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).Aims: To assess the efficacy and safety of fixed-dose combinations (FDCs) of tamsulosin and tadalafil compared with tadalafil monotherapy in patients with comorbid BPH-associated LUTS and ED.Methods: A randomized, double-blinded, active-controlled trial was conducted of 510 men with BPH-associated LUTS and ED. Patients were treated with FDCs of tamsulosin 0.4 mg plus tadalafil 5 mg (FDC 0.4/5 mg), tamsulosin 0.2 mg plus tadalafil 5 mg (FDC 0.2/5 mg), or tadalafil 5 mg for a 12-week treatment period. For a subsequent 12-week extension period, the patients were administered FDC 0.4/5 mg.Outcomes: The primary outcomes were changes from baseline in total International Prostate Symptom Score (IPSS) and International Index of Erectile Function erectile function domain (IIEF-EF) score at week 12 to prove superiority and non-inferiority of FDCs compared with tadalafil 5 mg. The safety assessments were adverse reactions, laboratory test results, and vital signs at week 24.Results: The mean changes in total IPSS and IIEF-EF scores were −9.46 and 9.17 for FDC 0.4/5 mg and −8.14 and 9.49 for tadalafil 5 mg, respectively, which indicated superiority in LUTS improvement (P = .0320) and non-inferiority in ED treatment with FDC 0.4/5 mg compared with tadalafil 5 mg. However, the results from FDC 0.2/5 mg failed to demonstrate superiority in LUTS improvement. No clinically significant adverse events regarding the investigational products were observed during the 24-week period.Clinical Implications: The FDC 0.4/5 mg is the first combined formulation of an α-blocker and a phosphodiesterase type 5 inhibitor that offers benefits in patient compliance and as add-on therapy in patients with comorbid BPH-associated LUTS and ED.Strengths and Limitations: The study clearly demonstrated the advantage of FDC 0.4/5 mg. The main advantage of FDC 0.4/5 mg was the enhanced efficacy on BPH-associated LUTS comorbidity with ED, the lower incidence of side effects, and the simplification and convenience of therapy, which led to better overall patient compliance. However, the lack of a tamsulosin monotherapy control group was a limitation of this study.Conclusion: The FDC 0.4/5 mg therapy was safe, well tolerated, and efficacious, indicating that combination therapy could provide clinical benefits for patients with BPH-associated LUTS complaints and ameliorate the comorbidity of ED.